Trial Profile
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Liposarcoma
- Focus Therapeutic Use
- Sponsors Vector Oncology Solutions LLC
- 18 Aug 2017 Results published in the Cancer.
- 18 Apr 2016 Status changed from active, no longer recruiting to completed.
- 15 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.